Corcept Therapeutics Incorporated
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | Corcept Therapeutics Incorporated |
Stock Symbol : | NASDAQ: CORT |
Class Period Start: | 08/02/2017 |
Class Period End: | 02/05/2019 |
Lead Plaintiff motion: | 05/13/2019 |
Date Filed: | 03/14/2019 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the Northern District of California |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the May 13, 2019 lead plaintiff deadline in a class action lawsuit filed against Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept” or “the Company”). The suit is pending in the U.S. District Court for the Northern District of California and investors, who purchased Corcept Therapeutics Incorporated securities between August 2, 2017 and February 5, 2019, have until May 13, 2019 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased Corcept Therapeutics Incorporated securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Corcept had improperly paid doctors to promote its drug, Korlym; Corcept aggressively promoted Korlym for off-label uses; Corcept’s sole specialty pharmacy was a related party; Corcept artificially inflated its revenue and sales using illicit sales practices through a related party; such practices were reasonably likely to lead to regulatory scrutiny; and as a result, defendants’ positive statements about Corcept’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. On February 5, 2019, a report published by Blue Orca Capital claimed that Corcept’s “sole specialty pharmacy and exclusive distributor is an undisclosed related party” and that the relationship “creates a material risk that the Company is using its captured pharmacy to boost sales, hide losses, or engage in other financial shenanigans.” Following this news, NASDAQ: CORT declined, causing investors harm. If you were negatively impacted by your investment in Corcept Therapeutics Incorporated securities between August 2, 2017 and February 5, 2019 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |